A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

Atrial Fibrillation

Time to the first occurrence of composite endpoint of stroke and non-CNS systemic embolism

• Time to the first occurrence of ISTH major bleeding • Time to the first occurrence of the composite of ISTH major and CRNM bleeding, Time to the first occurrence of composite endpoint of stroke, non-CNS systemic embolism, and ISTH major bleeding., Time to the first occurrence of composite endpoint of CV death, MI, stroke, and non-CNS systemic embolism., Time to CV death, Time to the first occurrence of composite endpoint of all-cause death, MI, stroke and non-CNS systemic embolism., Time to the first occurrence of composite endpoint of CV death, MI, stroke, acute limb ischemia (ALI [any unanticipated revascularization or amputation of ischemic limb]), and urgent hospitalization for vascular cause of ischemic nature (including DVT and PE).

No related papers found yet.

Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, Spain